A prospective observational safety study of patients with BRAFV600‐mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study). (10th February 2019) - Corrie, P.G.; Terheyden, P.; ten Tije, A.J.; Herbst, R.; Jansen, R.; Marples, M.; Debus, D.; Marconcini, R.; Blasinska‐Morawiec, M.; Freivogel, K.; Munson, M.L.G.; Goodman, G.R.; et al.